Endoscopic Determination of the Extent of Early Ulcerated Gastric Cancer by the Congo Red Test

Endoscopy ◽  
1982 ◽  
Vol 14 (02) ◽  
pp. 41-44 ◽  
Author(s):  
M. Tatsuta ◽  
S. Okuda ◽  
H. Tamura ◽  
H. Taniguchi
Keyword(s):  
Gastric Cancer ◽  
Congo Red ◽  
Congo Red Test

The 1Ntracutaneous Congo Red Test

1960 ◽  
Vol 6 (1) ◽  
pp. 92-101 ◽  
Author(s):  
W. K. C. Morgan
Keyword(s):  
Congo Red ◽  
Congo Red Test

DETERMINATION OF P53 GENE CODON 72 POLYMORPHISMS IN PATIENTS WITH GASTRIC CANCER

2013 ◽  
pp. 11-17
Author(s):  
Thi Tuy Ha Nguyen ◽  
Thi Minh Thi Ha
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
P53 Gene ◽  
Diffuse Gastric Cancer ◽  
Codon 72 ◽  
Cancer Group ◽  
Pcr Rflp ◽  
Gastric Cancer Patients ◽  
The Relationship

Background: The role of p53 gene in the gastric cancer is still controversial. This study is aimed at determining the rate of the p53 gene codon 72 polymorphisms in gastric cancer patients and evaluating the relationship between these polymorphisms and endoscopic and histopathological features of gastric cancer. Patients and methods: Sixty eight patients with gastric cancer (cases) and one hundred and thirty six patients without gastric cancer (controls) were enrolled. p53 gene codon 72 polymorphisms were determined by PCR-RFLP technique with DNA extracted from samples of gastric tissue. Results: In the group of gastric cancer, Arginine/Argnine, Arginine/Proline and Proline/Proline genotypes were found in 29.4%, 42.7% and 27.9%, respectively. The differences of rates were not statistically significant between cases and controls (p > 0,05). In males, the Proline/Proline genotype was found in 38.1% in patients with gastric cancer and more frequent in patients without gastric cancer (15.7%, p = 0,01). An analysis of ROC curve showed that the cut-off was the age of 52 in the Proline/Proline genotype, but it was 65 years old in the Arginine/Proline genotype. The Proline/Proline genotype was found in 41.9% in Borrmann III/IV gastric cancer, this rate was higher than Borrmann I/II gastric cancer (16.2%, p = 0.037) and also higher than controls (18.4%, p = 0,01). The rate of Proline/Proline genotype was 41.7% in the diffuse gastric cancer, it was higher than in controls (p = 0,023). Conclusion: No significative difference of rate was found in genotypes between gastric cancer group and controls. However, there was the relationship between Proline/Proline genotype and gastric cancer in males, Borrmann types of gastric cancer, the diffuse gastric cancer. Key words: polymorphism, codon 72, p53 gene, PCR - RFLP, gastric cancer.

Determination of Mutation of C-myc Oncogene in Gastric Cancer by Capillary Electrophoresis

2012 ◽  
Vol 39 (11) ◽  
pp. 1695-1700
Author(s):  
Xi-Hui XIE ◽  
Rong WANG ◽  
Zheng-Ping JIA ◽  
Hua XIE ◽  
Ai-Mei ZHAMG ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Capillary Electrophoresis ◽  
Myc Oncogene

Can the use of an endoscopic Congo red test decrease the incidence of incomplete proximal gastric vagotomy?

1987 ◽  
Vol 33 (6) ◽  
pp. 427-431 ◽  
Author(s):  
Philip E. Donahue ◽  
Junichi Yoshida ◽  
Harry M. Richter ◽  
C. Thomas Bombeck ◽  
Lloyd M. Nyhus ◽  
...  
Keyword(s):  
Congo Red ◽  
Proximal Gastric Vagotomy ◽  
Congo Red Test ◽  
Endoscopic Congo Red Test

scholarly journals Comparison between Mononucleotide and Dinucleotide Marker Panels in Gastric Cancer with Loss of hMLH1 or hMSH2 Expression

2017 ◽  
Vol 32 (3) ◽  
pp. 352-356 ◽  
Author(s):  
Jeong Goo Kim ◽  
Soyoung Shin ◽  
Joonhong Park
Keyword(s):  
Gastric Cancer ◽  
High Sensitivity ◽  
Size Change ◽  
Marker Panel ◽  
Dna Mismatch ◽  
Repair Deficiency ◽  
Msi Analysis ◽  
Analytical Sensitivities ◽  
Dna Mismatch Repair Deficiency

Background DNA mismatch repair deficiency is an important molecular mechanism of genetic instability in gastric cancer, and a high instability at microsatellites is associated with favorable prognosis. We compared mononucleotide and dinucleotide microsatellite instability (MSI) marker panels in 56 paired gastric tumor and normal samples. Methods The mononucleotide marker panel (mono panel) consisted of 8 markers: BAT25, BAT26, BAT40, BAT-RII, NR21, NR22, NR24 and NR27. The dinucleotide marker panel (di panel) contained D2S123, D5S346, D17S250, D17S261, D17S520, D18S34 and D18S58. The NCI panel was used as reference panel. Results Among 13 gastric tumors showing no hMLH1 or hMSH2 expression, 8 MSI-H (high) and 5 MSI-L (low) were identified. The analytical sensitivities of the NCI, mono and di panels to detect unstable MSI were 61.5% (8/13), 76.9% (10/13) and 84.6% (11/13), respectively. The size change of allele shift was statistically greater in the mono panel than in the di panel (p = 0.02 by Mann-Whitney U-test). The BAT40 (69.2%, 9/13) and D18S34 (76.9%, 10/13) markers showed high sensitivity for determination of MSI status. Conclusions To improve the detection rate of MSI in gastric cancer with loss of hMLH1 or hMSH2 expression, the kind of MSI marker may need to be considered more, instead of the repetitive type of marker. Thus, an MSI panel designed with a combination of both BAT40 and D18S34 is suggested for providing more accurate and sensitive MSI analysis in gastric cancer.

scholarly journals Serum YKL-40 Levels in Patients with Gastric Cancer

2011 ◽  
Vol 3 ◽  
pp. BIC.S7154 ◽  
Author(s):  
Veyis Itik ◽  
Ozgur Kemik ◽  
Ahu Kemik ◽  
A. Cumhur Dulger ◽  
Aziz Sümer ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Colorectal Cancers ◽  
Healthy Population ◽  
Serum Samples ◽  
Future Studies ◽  
Male Patients

Aims and background YKL-40 is secreted by several types of tumors. Increased serum YKL-40 levels have been reported in prostate, glioblastoma, breast and colorectal cancers. Determination of YKL-40 levels may serve as a valuable biomarker for the diagnosis and treatment of gastric cancer. The purpose of this study was to determine the serum YKL-40 levels expressed in gastric carcinomas. Methods Between 2009 and 2011, we retrospectively reviewed 100 patients with gastric cancer and compared their serum samples to 75 healthy volunteers. YKL-40 levels were determined by an enzyme-linked immunosorbent assay (ELISA). Results We found significantly higher serum levels of YKL-40 in patients with gastric cancer compared to the healthy population ( P < 0.0001). We also found significant differences in serum YKL-40 levels between female and male patients with gastric cancer ( P < 0.01). Conclusions YKL-40 is over-expressed in gastric cancer, suggesting a more aggressive phenotype. YKL-40 may be a useful serum biomarker for gastric cancer identification, and future studies should focus on the role of YKL-40 in the tumorigenesis of gastric cancer and responsiveness toward treatment.

Sign in / Sign up

Export Citation Format

Share Document